It is an insulin sensitizer, but unfortunately has been seen to have bad effect on urinary bladder in long term use.
Cannot the harmful effect producing fraction of molecule be silenced in some way, so that a good drug will remain in the armour of the physicians?
The FDA has approved updated label information for pioglitazone (Actos) and medications that contain it, following its warning in June about bladder cancer risk with the drug.
The new labeling, released Friday, warns that use of pioglitazone for more than a year may increase the risk of bladder cancer, a finding based on an interim analysis of an epidemiological study.
Pioglitazone is the second medication in the thiazolidinedione (TZD) class to be associated with serious side effects. Last fall, use of rosiglitazone (Avandia) was severely restricted in the U.S. because of concerns over heart attack risk.